April 29, 2016
Remimazolam provided adequate sedation in patients undergoing colonoscopy with a superior success rate compared with midazolam, according to the results of a phase 2b trial.
“Remimazolam is a benzodiazepine developed to provide sedative effects with a short half-life (terminal elimination half-life 0.75 hours compared with 4.29 hours for midazolam) translating into a quick onset and offset of effect,” the researchers wrote. “This ester-based drug is rapidly hydrolyzed in the body by tissue esterases to an inactive carboxylic acid metabolite. To date, three clinical trials for procedural sedation have been completed and reported, and this manuscript describes the fourth.”